Carnitine Deficiency & Fatty Acid Oxidation Disorders in Adult Medicine: A Clinical Review

Dr Neeraj Manikath , claude.ai

Abstract

Fatty acid oxidation disorders (FAODs) and carnitine deficiency syndromes, traditionally considered pediatric conditions, increasingly present diagnostic challenges in adult internal medicine. This review examines five critical clinical scenarios: valproate-induced carnitine depletion, primary systemic carnitine deficiency presenting as adult-onset cardiomyopathy, riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency, the diagnostic approach to metabolic myopathies, and CPT II deficiency as the leading cause of recurrent myoglobinuria in adults. We provide evidence-based approaches to recognition, diagnosis, and management, with practical clinical pearls derived from contemporary literature and bedside experience.

Introduction

The oxidation of long-chain fatty acids provides the primary energy substrate during fasting, prolonged exercise, and periods of metabolic stress. Carnitine serves as the essential shuttle mechanism transporting long-chain fatty acids across the inner mitochondrial membrane, where beta-oxidation occurs. Disruption of this pathway—whether acquired or hereditary—produces a spectrum of clinical manifestations ranging from asymptomatic biochemical abnormalities to life-threatening metabolic decompensation. While newborn screening has identified many pediatric cases, adult presentations remain underdiagnosed, often masquerading as common conditions like idiopathic cardiomyopathy, recurrent rhabdomyolysis, or unexplained encephalopathy.

Valproate-Induced Carnitine Depletion & Hyperammonemia: Prophylaxis & Treatment

Pathophysiology and Clinical Presentation

Valproate causes dose-dependent carnitine depletion through multiple mechanisms: increased renal excretion of acylcarnitines, sequestration of free carnitine as valproylcarnitine, and inhibition of carnitine biosynthesis. This depletion impairs hepatic fatty acid oxidation and ureagenesis, precipitating hyperammonemia even with therapeutic valproate levels (1,2). The incidence of symptomatic hyperammonemia ranges from 5-35% depending on the population studied, with higher rates in polytherapy regimens and underlying metabolic vulnerabilities (3).

Clinical Pearl: Valproate-associated hyperammonemic encephalopathy (VHE) can occur with normal liver enzymes and therapeutic drug levels. The classic presentation includes altered mental status, vomiting, and focal neurological signs appearing weeks to years after valproate initiation. Unlike hepatotoxicity, aminotransferases typically remain normal.

Diagnostic Approach

The diagnosis requires a high index of suspicion. Obtain serum ammonia in any valproate-treated patient with altered mentation, even without liver dysfunction. Plasma carnitine levels (total and free) should be measured, though symptoms may occur despite "low-normal" values. The free carnitine to total carnitine ratio typically falls below 0.4 in significant depletion (4).

Bedside Hack: In the acute setting, empiric L-carnitine supplementation can be both diagnostic and therapeutic. Clinical improvement within 24-72 hours after carnitine administration supports the diagnosis and obviates the need to discontinue valproate in many cases.

Treatment and Prophylaxis

For acute VHE, intravenous L-carnitine 100 mg/kg loading dose (maximum 6 grams) followed by 50 mg/kg/day in divided doses demonstrates rapid reversal of encephalopathy and hyperammonemia (5). Ammonia-lowering adjuncts (lactulose, rifaximin) provide limited benefit as the pathophysiology differs from hepatic encephalopathy.

Regarding prophylaxis, consensus remains elusive. The American Academy of Neurology does not recommend routine supplementation for all patients (6). However, high-risk populations—including those receiving polytherapy, with developmental disabilities, organic acidemias, or prior episodes of VHE—warrant prophylactic supplementation with 50-100 mg/kg/day of oral L-carnitine (7).

Oyster: Monitor carnitine levels every 6-12 months in patients on chronic valproate, particularly those with risk factors. Free carnitine below 20 μmol/L warrants supplementation regardless of symptoms.

Primary Systemic Carnitine Deficiency (OCTN2 Defect): The Adult-Onset Dilated Cardiomyopathy Presentation

Molecular Basis and Epidemiology

Primary carnitine deficiency results from biallelic mutations in SLC22A5, encoding the OCTN2 carnitine transporter. This causes impaired cellular carnitine uptake with profound plasma deficiency (typically <5 μmol/L; normal 25-50 μmol/L). While classic presentation involves infantile hypoketotic hypoglycemia and cardiomyopathy, approximately 20-30% of cases present in adulthood (8,9).

Adult Clinical Manifestations

The adult phenotype predominantly features progressive dilated cardiomyopathy, often diagnosed in the third to fifth decade. Patients present with heart failure symptoms: dyspnea, fatigue, reduced exercise tolerance, and arrhythmias. Skeletal muscle weakness may be subtle or absent. Cardiac MRI typically shows left ventricular dilatation with reduced ejection fraction, often mimicking idiopathic dilated cardiomyopathy (10).

Clinical Pearl: Consider primary carnitine deficiency in any adult with unexplained dilated cardiomyopathy, particularly with family history of sudden cardiac death or cardiomyopathy, concurrent muscle weakness, or unexplained hypoglycemia during illness. The diagnosis is tragically missed because carnitine levels are not routinely measured in cardiomyopathy workups.

Diagnosis and Family Screening

Diagnosis requires demonstration of markedly reduced free carnitine (<5 μmol/L, often <2 μmol/L) with absent or minimal increase in acylcarnitines. Genetic confirmation via SLC22A5 sequencing establishes the diagnosis definitively. Functional studies demonstrate defective carnitine uptake in cultured fibroblasts when genetic testing is inconclusive (11).

Oyster: Screen first-degree relatives of probands. Heterozygotes may have mildly reduced carnitine levels (15-20 μmol/L) but remain asymptomatic. Homozygous siblings identified through cascade screening benefit from presymptomatic treatment.

Treatment and Prognosis

High-dose oral L-carnitine (100-400 mg/kg/day in divided doses, typically 3-6 grams daily in adults) achieves plasma concentrations sufficient to overcome the transport defect through mass action. Treatment produces dramatic clinical improvement: normalization of cardiac function, resolution of muscle weakness, and prevention of metabolic decompensation (12). Echocardiographic improvement may occur within 3-6 months, with some patients achieving complete normalization of ventricular function.

Bedside Hack: Patients require lifelong compliance with divided daily dosing (every 6-8 hours) to maintain therapeutic levels. Gastrointestinal side effects (fishy odor, diarrhea) can be mitigated by gradual dose escalation and taking with meals.

Riboflavin-Responsive Multiple Acyl-CoA Dehydrogenase Deficiency (RR-MADD)

Pathophysiology

Multiple acyl-CoA dehydrogenase deficiency results from defects in electron transfer flavoproteins (ETF or ETF-dehydrogenase), causing impaired activity of all flavin-dependent acyl-CoA dehydrogenases. This produces a combined defect in fatty acid, amino acid, and choline metabolism. Certain genotypes, particularly milder ETF-QO mutations, respond dramatically to riboflavin (vitamin B2) supplementation (13,14).

Clinical Spectrum in Adults

Adult-onset RR-MADD typically presents between ages 20-40 with exercise intolerance, proximal muscle weakness (often fluctuating), recurrent myoglobinuria, and lipid storage myopathy. Unlike classic infantile forms with severe hypoglycemia and metabolic acidosis, adults exhibit milder phenotypes. Some patients report lifelong exercise intolerance, while others develop symptoms after precipitants like infections, fasting, or pregnancy (15).

Clinical Pearl: The "riboflavin-responsive myopathy" phenotype classically presents with symmetric proximal weakness, exercise intolerance, and significantly elevated creatine kinase (often 1000-5000 U/L at baseline). Weakness characteristically fluctuates, improving after rest and worsening with exertion or fasting.

Diagnostic Workup

Acylcarnitine profile reveals a characteristic pattern: elevations in multiple species including C4, C5, C8, C10, C12, C14, and C14:1—the "all across the board" pattern reflecting the multiple enzyme deficiencies. Urine organic acid analysis demonstrates elevated glutaric acid, ethylmalonic acid, and various dicarboxylic acids. Muscle biopsy shows lipid accumulation. Genetic testing of ETFA, ETFB, and ETFDH confirms the diagnosis (16).

Oyster: The acylcarnitine pattern in MADD differs from isolated FAODs by showing elevations across short-, medium-, and long-chain species simultaneously. This "shotgun" pattern should immediately prompt consideration of MADD.

Treatment Response

Riboflavin supplementation (100-400 mg daily) produces remarkable clinical and biochemical improvement in responsive genotypes, often within weeks. Patients report increased strength, exercise tolerance, and normalized creatine kinase. Some require additional therapies: L-carnitine supplementation (50 mg/kg/day), coenzyme Q10, dietary modification with frequent meals and complex carbohydrates, and avoidance of fasting (17).

Bedside Hack: Conduct a riboflavin trial (200 mg twice daily for 2-3 months) in any patient with suspected MADD while awaiting genetic confirmation. Monitor creatine kinase and functional status. Response predicts long-term prognosis and confirms riboflavin-responsive genotype.

The Rhabdomyolysis "Metabolic Myopathy" Workup: Acylcarnitine Profile, Carnitine Levels, & Urine Organic Acids

When to Suspect Metabolic Myopathy

Recurrent rhabdomyolysis (≥2 episodes), exercise-induced myoglobinuria, exertional cramps with pigmenturia, family history of similar symptoms, or rhabdomyolysis with atypical triggers warrants metabolic investigation. Traditional causes (trauma, drugs, toxins, infections) should be excluded (18).

The Metabolic Panel: What to Order and When

During acute rhabdomyolysis:

• Plasma acylcarnitine profile (before carnitine supplementation)
• Free and total carnitine levels
• Creatine kinase (often >10,000 U/L)
• Basic metabolic panel (assess for acute kidney injury)
• Urine myoglobin

During recovery (2-4 weeks post-event):

• Repeat fasting acylcarnitine profile
• Urine organic acids (first morning void)
• Consider forearm exercise testing (if glycogen storage disease suspected)
• Genetic panel for metabolic myopathies

Clinical Pearl: Samples obtained during acute episodes provide highest diagnostic yield. Acylcarnitine abnormalities may normalize between episodes in some FAODs. If initial testing is normal but suspicion remains high, repeat during a subsequent episode or after provocative testing (controlled fasting under supervision).

Interpretation Patterns

CPT II deficiency: Decreased long-chain acylcarnitines (C16, C18) with normal or low free carnitine during acute episodes. Between episodes, may show normal profiles.

VLCAD deficiency: Elevated C14:1 (tetradecenoylcarnitine) with increased C14:1/C2 ratio.

MADD: Generalized elevation of multiple acylcarnitine species (C4-C18), elevated urine glutaric and ethylmalonic acids.

Carnitine deficiency: Markedly low free carnitine (<5 μmol/L), low total carnitine, normal or decreased acylcarnitines (19).

Oyster: Normal carnitine levels do not exclude FAODs. Many FAODs present with normal or only mildly reduced carnitine. The acylcarnitine pattern provides more specific diagnostic information than total carnitine levels alone.

Additional Diagnostic Considerations

Muscle biopsy with electron microscopy and specialized staining (Oil Red O for lipid droplets) demonstrates lipid storage myopathy in many FAODs. Enzyme assays in cultured fibroblasts or leukocytes confirm specific defects. Next-generation sequencing gene panels for metabolic myopathies provide comprehensive genetic diagnosis (20).

Carnitine Palmitoyltransferase II (CPT II) Deficiency: The Most Common Cause of Recurrent Myoglobinuria in Adults

Molecular Basis and Prevalence

CPT II, located on the inner mitochondrial membrane, catalyzes the final step in long-chain fatty acid transport: transfer of the acyl group from carnitine back to CoA. Mutations in CPT2 cause three phenotypes: lethal neonatal, severe infantile hepatocardiomuscular, and adult myopathic forms. The adult myopathic form, caused by the common p.Ser113Leu mutation, represents the most prevalent inherited cause of recurrent myoglobinuria, with estimated prevalence of 1:500 to 1:2000 (21,22).

Clinical Presentation

The classic presentation involves recurrent episodes of exercise-induced muscle pain, stiffness, and myoglobinuria, typically triggered by prolonged exercise (especially in cold temperatures), fasting, infections, or emotional stress. Episodes characteristically occur hours after exercise cessation, often during sleep following a day of exertion. Between episodes, patients remain asymptomatic with normal strength and creatine kinase (23).

Clinical Pearl: The pathognomonic history involves "second-wind" phenomenon in reverse: unlike McArdle disease where patients experience relief with continued exercise, CPT II patients develop worsening symptoms 4-12 hours post-exertion, frequently awakening with severe myalgia and dark urine.

Triggers and Risk Factors

Specific triggers include:

• Prolonged aerobic exercise (>30-60 minutes)
• Cold exposure during exercise
• Fasting or low-carbohydrate diets
• Febrile illnesses or infections
• General anesthesia
• Certain medications (ibuprofen, isotretinoin, valproate)

Oyster: Young adult males predominate in clinical series (70-80% male), possibly due to increased muscle mass, exercise intensity, or hormonal factors. However, diagnosis should not be excluded in females, particularly those with compatible histories (24).

Diagnosis

Biochemical testing:

• Acylcarnitine profile during acute episodes may show decreased C16 and C18:1 species with accumulation of long-chain acylcarnitines
• Free carnitine often normal or mildly reduced
• Between episodes, biochemical testing may be entirely normal

Genetic testing: The p.Ser113Leu (c.338C>T) variant accounts for 60-80% of adult myopathic CPT II deficiency alleles in European populations. Genetic testing provides definitive diagnosis and enables presymptomatic family screening (25).

Enzyme assay: CPT II activity measurement in muscle, fibroblasts, or lymphocytes demonstrates reduced activity (typically 15-25% of normal in adult form).

Bedside Hack: In patients with compelling history but normal interictal testing, consider genetic testing for CPT2 as first-line investigation. The high prevalence of the common p.Ser113Leu variant makes genetic diagnosis highly feasible and cost-effective.

Management and Prognosis

Acute management:

• Aggressive intravenous hydration with alkalinization to prevent acute tubular necrosis
• Monitor renal function and electrolytes
• Avoid nephrotoxic agents
• Discontinue triggering medications

Preventive strategies:

• Avoid prolonged fasting (meals every 3-4 hours during waking)
• High-carbohydrate diet (>60% calories from carbohydrates), especially before and during exercise
• Modify exercise: frequent rest periods, avoid cold exposure, gradual warm-up
• Triheptanoin (odd-chain triglyceride) supplementation shows promise in recent studies
• Some advocate for medium-chain triglyceride supplementation, though evidence remains limited
• L-carnitine supplementation (debated; may theoretically worsen acylcarnitine accumulation)

Clinical Pearl: Pre-exercise carbohydrate loading significantly reduces episode frequency. Instruct patients to consume complex carbohydrates 1-2 hours before exercise and avoid exercise during fasting or illness.

Oyster: Despite dramatic presentations, long-term prognosis is excellent with appropriate lifestyle modifications. Most patients remain fully functional with normal life expectancy. The primary risks involve acute kidney injury during severe episodes and rare reports of respiratory failure requiring ventilatory support (26).

Genetic Counseling

CPT II deficiency follows autosomal recessive inheritance. Heterozygotes remain asymptomatic. Affected individuals should receive genetic counseling regarding reproductive implications. Prenatal and preimplantation genetic diagnoses are available for families desiring such interventions.

Conclusion and Clinical Synthesis

Carnitine deficiency syndromes and FAODs, while individually rare, collectively represent an important differential in multiple common adult presentations: unexplained cardiomyopathy, recurrent rhabdomyolysis, chronic fatigue syndromes, and encephalopathy in specific contexts. The advent of accessible genetic testing and improved biochemical assays has facilitated diagnosis, yet these conditions remain underrecognized in adult medicine.

Key clinical scenarios warranting consideration include: (1) unexplained dilated cardiomyopathy, particularly in younger patients—measure plasma carnitine; (2) recurrent rhabdomyolysis without clear etiology—obtain acylcarnitine profile and genetic testing for CPT2; (3) valproate-treated patients with encephalopathy and normal liver function—check ammonia and carnitine levels; (4) proximal myopathy with fluctuating weakness—consider MADD and trial riboflavin.

The dramatic treatment responses possible in these conditions—carnitine supplementation reversing cardiomyopathy, riboflavin eliminating muscle weakness, dietary modification preventing life-threatening rhabdomyolysis—underscore the importance of maintaining diagnostic vigilance. Simple, relatively inexpensive biochemical tests can identify these treatable conditions, transforming patient outcomes and preventing serious morbidity.

References

1. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009;47(2):101-111.

2. Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother. 2010;44(7-8):1287-1293.

3. Gidal BE, Inglese CM, Meyer JF, et al. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol. 1997;16(4):301-305.

4. Silva MF, Aires CC, Luis PB, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008;31(2):205-216.

5. Chopra A, Kolla BP, Mansukhani MP, et al. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry. 2012;34(3):290-298.

6. Grünert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. Orphanet J Rare Dis. 2014;9:117.

7. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother. 2000;34(5):630-638.

8. Spiekerkoetter U, Lindner M, Santer R, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis. 2009;32(4):488-497.

9. El-Hattab AW, Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab. 2015;116(3):107-112.

10. Spiekerkoetter U, Bastin J, Gillingham M, et al. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis. 2010;33(5):555-561.

11. Rasmussen J, Nielsen OW, Lund AM, et al. Primary carnitine deficiency and pivalic acid exposure causing encephalopathy and fatal cardiac events. J Inherit Metab Dis. 2013;36(1):35-41.

12. Wilcken B, Wiley V, Sim KG, Carpenter K. Carnitine transporter defect diagnosed by newborn screening with electrospray tandem mass spectrometry. J Pediatr. 2001;138(4):581-584.

13. Olsen RK, Olpin SE, Andresen BS, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 2007;130(Pt 8):2045-2054.

14. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130(Pt 8):2037-2044.

15. Angelini C, Vergani L, Martinuzzi A. Clinical and biochemical aspects of carnitine deficiency and insufficiency. Transport and metabolism of carnitine in muscle. Mol Aspects Med. 2004;25(5-6):533-549.

16. Cornelius N, Frerman FE, Corydon TJ, et al. Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum Mol Genet. 2012;21(15):3435-3448.

17. Henriques BJ, Rodrigues JV, Olsen RK, et al. Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation. J Biol Chem. 2009;284(7):4222-4229.

18. Scalco RS, Gardiner AR, Pitceathly RD, et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. 2015;10:51.

19. Tein I. Carnitine transport and fatty acid oxidation. Mol Genet Metab. 2003;78(3):163-172.

20. Orngreen MC, Norgaard MG, Sacchetti M, et al. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2004;56(2):274-278.

21. Joshi PR, Deschauer M, Zierz S. Carnitine palmitoyltransferase II (CPT II) deficiency: genotype-phenotype analysis of 50 patients. J Neurol Sci. 2014;338(1-2):107-111.

22. Ørngreen MC, Vissing J. Treatment opportunities in patients with metabolic myopathies. Curr Treat Options Neurol. 2017;19(11):37.

23. Isackson PJ, Bennett MJ, Lichter-Konecki U, et al. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab. 2008;94(4):422-427.

24. Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. Lab Invest. 2003;83(11):1543-1554.

25. Fanin M, Anichini A, Cassandrini D, et al. Allelic and phenotypic heterogeneity in 49 Italian patients with the myopathic form of CPT-II deficiency. Clin Genet. 2012;82(3):232-239.

26. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153-162.

---

Author's Note: This review synthesizes current evidence regarding adult presentations of carnitine and fatty acid oxidation disorders. Clinicians should maintain high diagnostic suspicion in compatible presentations, as early recognition enables life-changing interventions. Collaboration with metabolic specialists enhances diagnostic accuracy and treatment optimization.